Background: Although 40% to 50% of patients with chronic heart failure (HF) have relatively preserved systolic function (PSF), few trials have been conducted in this population and treatment guidelines do not include evidence-based recommendations. Methods and Results: The Irbesartan in Heart Failure with Preserved Systolic Function (I-PRESERVE) is enrolling 4100 subjects with HF-PSF to evaluate whether 300 mg irbesartan is superior to placebo in reducing mortality and prespecified categories of cardiovascular hospitalizations. The principal inclusion criteria are age $60 years, heart failure symptoms, an ejection fraction $45%, and either hospitalization for heart failure within 6 months or corroborative evidence of heart failure or the substrate for diastolic heart failure. Additional secondary end points include cardiovascular mortality, cause-specific mortality and morbidity, change in New York Heart Association functional class, quality of life, and N-terminal pro-BNP measurements. Follow-up will continue until 1440 patients experience a primary end point. Substudies will evaluate changes in echocardiographic measurements and serum collagen markers. Conclusion: I-PRESERVE is the largest trial in this understudied area and will provide crucial information on the characteristics and course of the syndrome, as well as the efficacy of the angiotensin receptor blocker irbesartan.
Chronic heart failure (CHF) is a major and growing cause of cardiovascular morbidity and mortality in patients throughout the world. 1 Previously, it had often been assumed that most CHF patients have underlying systolic dysfunction, which is responsible for their clinical presentation. However, it has become increasingly apparent over the last decade that many heart failure patients have a normal or nearly normal ejection fractionddescribed as heart failure with preserved systolic function (HF-PSF). 2, 3 Database reviews report a prevalence ranging from 40% to 71%. 4 For example, the Framingham Heart Study reported a 51% prevalence of HF-PSF (defined as a left ventricular ejection fraction [LVEF] $50%) 5 whereas the Cardiovascular Health Study reported 55% of existing heart failure subjects with HF-PSF (LVEF O50%). 6 More recently, the EuroHeart Failure Survey noted that among patients enrolled after hospitalization for heart failure, 49% of men and 72% of women had an LVEF of 40% or more. 7 In addition, the Acute Decompensated Heart Failure National Registry (ie, ADHERE) reported that in acute decompensated HF patients with documented measurement of LVEF, fully 51% of patients had preserved systolic function (LVEF $0.40). 8 Although these data consistently indicate that HF-PSF is a problem of significant clinical magnitude, few clinical trials have been conducted in this specific patient population and there is no proven therapy. As a result, without evidence-based recommendations, guideline groups such as the European Society of Cardiology currently suggest that HF-PSF be treated with b-blockers, verapamil-type calcium antagonists, angiotensin-converting enzyme (ACE) inhibitors, or diuretics, based only on specific patient comorbid conditions. 9 In clinical practice, medical treatment has been largely empiric.
The widespread role of the renin-angiotensin system (RAS) in cardiovascular disease, particularly in systolic heart failure, has led to investigation of RAS inhibitors in HF-PSF. Specifically the angiotensin receptor blockers (ARBs) have been of interest because of their ability to more completely antagonize the effects of angiotensin II and their excellent tolerability. The only prospective outcome trial in HF-PSF, the recently completed CHARM-PRESERVED study, 10 reported results that suggested a promising role for ARBs in HF-PSF, although these results cannot be seen as conclusive.
The Irbesartan in Heart Failure with Preserved Systolic Function (I-PRESERVE) trial, the largest trial in this understudied area, was designed to definitively test the hypothesis that an ARB, irbesartan, would improve clinical outcomes in patients with HF-PSF. The purpose of this article is to describe the protocol and processes that will be used to collect data and to test the hypothesis of the trial.
Design of the I-PRESERVE Trial Objectives
The objectives of I-PRESERVE trial are to study the effects of irbesartan on morbidity and mortality outcomes, symptom scores, and quality of life in a patient population with heart failure and preserved systolic function.
Study Population
Specific inclusion criteria are listed in Table 1 . These inclusion criteria were designed to enroll a patient population similar to that observed in epidemiologic and communitybased studies, with ongoing heart failure symptoms and an increased likelihood of clinical events. Thus the requirement for age $60 years, LVEF $45%, and recent hospitalization for heart failure or moderate to severe symptoms and corroborative objective evidence of heart failure or a cardiac substrate for diastolic dysfunction were required for the study.
The exclusion criteria are shown in Table 2 . These were designed to exclude patients with confounding medical conditions or an inability to meaningfully participate in the trial.
Study Design
I-PRESERVE is a placebo-controlled, double-blind, multicenter, international, parallel-group study. Figure 1 summarizes the study design. Subjects are randomized according to a 1:1 ratio of irbesartan to placebo, stratified by site and by use of ACE inhibitors at baseline, using an automated, central randomization system. ACE inhibitor use is limited to those patients with a specific indication other than hypertension (such as diabetes mellitus with complications and significant coronary or peripheral artery disease), In addition, only one third of patients at each site are permitted to be randomized with ACE inhibitor concomitant therapy.
This study will be conducted according to the ethical principles described in the Declaration of Helsinki and will have received Institutional Review Board/Independent Ethics Committee approval before initiation. Freely given written informed consent must be obtained from every subject before trial participation.
Study Endpoints
The primary end point is defined as time from randomization to the first occurrence of the composite outcome of death (all cause) or cardiovascular hospitalization. Cardiovascular hospitalizations are defined as:
Protocol specified cardiovascular hospitalizations for a primary cause of: worsening heart failure, unstable angina, myocardial infarction, ventricular dysrhythmia, atrial dysrhythmia, or stroke.
The endpoint additionally includes myocardial infarction or stroke occurring during any hospitalization at any point during the study.
Secondary endpoints include the effect of irbesartan as compared with placebo in reducing the risk of: cardiovascular death; all-cause mortality; combined vascular endpoint: cardiovascular death, nonfatal myocardial infarction (MI) or nonfatal stroke; or combined HF endpoint: HF mortality or hospitalizations; the effect of irbesartan as compared with placebo on: quality of life as measured by the Minnesota Living with Heart Failure questionnaire, change in New York Heart Association (NYHA) functional class, change in patient global assessment of symptoms, N-terminal B-type natriuretic peptide levels in blood.
Sample Size and Statistical Plan
The trial was designed to provide 90% power to detect a 14.5% reduction in the primary event rate with a 2-sided type I error rate of 0.05, which would require a total of 1440 patients to experience a first, primary event. The sample size was estimated based on data from the placebo group in the Digitalis Investigation Group ancillary trial in which 998 patients with LVEF O45% were followed for a mean of 36 months. Using similar endpoints, an annual primary event rate (death of any cause or cardiovascular hospitalizations) of 18% was estimated for the placebo group. With this projected event rate, a sample size of at least 3600 subjects with 2 years of uniform recruitment and a minimum follow-up of 2 years was anticipated to attain 1440 primary events. By the second year of the study, it became apparent that the total event rate was lower than projected. As a result, in April 2004, the I-PRESERVE Executive Committee recommended an increase in the sample size to 4100 patients to reach the requisite 1440 events within the initial projected timeline.
The primary end point and secondary end points based on clinical outcomes will be analyzed based on the time to the first occurrence. Survival curves by treatment will be estimated using the Kaplan-Meier procedure and compared using a 2-sided log-rank test. The treatment effect will be modeled using Cox proportional hazards models and adjusted relative risks will be estimated from them.
Substudies
Two formal substudies are being conducted by selected I-PRESERVE sites: to be elevated in heart failure, although no data exist in HF-PSF. This study will measure peripheral collagen markers, pro-collagen Type III and osteopontin, at baseline and 6 months. The primary objective will be to compare change in pro-collagen Type III between irbesartan and placebo. Secondary objectives will measure differences in treatment groups with collagen markers and the relation of baseline values to the primary clinical outcome. The study is designed for enrollment of 312 subjects to yield at least 200 samples.
Organization
The I-PRESERVE Executive Committee includes 2 coprincipal investigators and 4 other membersdall of whom are cardiologists. The committee receives operational assistance from representatives of the sponsoring companies, Bristol-Myers Squibb and Sanofi-Aventis, who are exofficio members. The Executive Committee was responsible for the development of the study protocol and amendments and overseeing the conduct of the trial. The Executive Committee also functions as the Publication Committee for this trial. A Steering Committee, consisting of the Executive Committee plus the national coordinators from the participating countries, provides additional scientific input to the Executive Committee and guidance on the logistics of the study. An End-Point Adjudication Committee reviews all clinical events during the trial and adjudicates all study endpoints. The Endpoint Committee chair is a member of the Executive Committee.
The Data Safety Monitoring Board is independent of the study committees and operational teams. At least 2 interim evaluations of all-cause mortality are planned and will use predefined stopping rules for major safety concerns.
Discussion
Despite the growing importance of HF-PSF, this remains an understudied area. The paucity of clinical trials in HF-PSF reflects a number of factors, including the relatively recent recognition of the existence and importance of this condition, disagreement concerning its pathophysiology as well as lack of a simple and straightforward diagnostic test. However, our understanding of the syndrome is increasing, and there is growing evidence that most patients with this presentation have underlying left ventricular diastolic dysfunction. Recent mechanistic studies in patients with heart failure and LVEF O50%, in whom other etiologies such as valvular, pericardial disease, and high output states have been excluded, indicate that there are demonstrable abnormalities of diastolic functiondparticularly impaired relaxation or reduced left ventricular compliance. 11, 12 Echocardiographic abnormalities, such as abnormalities of mitral valve flow and annular velocities, pulmonary venous flow, pulmonary artery pressures, and left atrial size are usually present, although they are not specific for diastolic dysfunction. Elevated natriuretic peptide levels are also often present, although these are also not specific for this diagnosis.
Epidemiologic and cohort studies provide consistent information about the characteristics of patients of patients with HF-PSF. [3] [4] [5] [6] These patients are generally older than those with systolic dysfunction and much more likely to be women. The majority have a history of hypertension, which often persists after the development of heart failure. Although many may have underlying coronary disease, previous myocardial infarction is far less common than in patients with systolic dysfunction. These characteristics are consistent with the importance of left ventricular hypertrophy and ''aging myocardium'' (presbycardia) as mechanisms of diastolic dysfunction. Although mechanistic studies, as discussed previously, demonstrate that abnormalities of diastolic function are invariably present in HF-PSF patients, reviews of larger less-controlled databases have noted that indices of diastolic function are also frequently abnormal in elderly patients who are without symptoms and also note the high rate of comorbidites. 4 There is, then, disagreement concerning the relative contribution of diastolic dysfunction to heart failure in a population prone to other comorbidities. Therefore, unlike in systolic heart failure, in which the concepts linking systolic dysfunction and remodeling to the development and progression of the syndrome are increasingly understood and accepted, there is still controversy about the development and progression of HF-PSF. However, as in systolic heart failure, preclinical and clinical evidence suggest that the RAS is a contributing factor in the development of HF-PSFd principally through the trophic effects of angiotensin II in the vasculature and myocardium, but perhaps also through myocardial fibrosis mediated by aldosterone. 13, 14 Although several animal models of diastolic dysfunction have been available, only recently has an animal model of HF-PSF become available: Dahl salt-sensitive rats fed a high salt diet beginning at 7 weeks developed high blood pressure, compensated left ventricular hypertrophy (LVH), and later transitioned into HF-PSF. Unlike previous models, these animals developed heart failure in the absence of systolic dysfunction. In these rats, treatment with an ARB blocked the progression to LVH and transition into HF-PSF. 15 Clinical trials investigating the effects of RAS inhibition, using either ACE inhibitors or ARBs, in HF-PSF are still limited but increasing. Several small studies provided the first evidence that these agents may be effective in this setting. A retrospective analysis of Vasodilator Heart Failure Trial (ie, V-HeFT) I and II for LVEF O35% patients (mean LVEF 46%) suggested benefit for the ACE inhibitor enalapril. 16 In a placebo-controlled crossover study, the ARB losartan was shown to increase exercise tolerance and improve quality of life in subjects with diastolic dysfunction and a hypertensive response to exercise. 17 Finally, in an outcomes trial, CHARM-PRESERVED, the ARB candesartan reduced hospitalizations for HF, but did not significantly reduce the primary composite endpoint of cardiovascular death or HF hospitalization. 10 Thus, although there is a strong mechanistic rationale for further investigation of RAS inhibitors in this clinical syndrome, there remains a lack of clinical data upon which to base guidelines for the use of these agents in treatment of HF-PSF.
The ARB irbesartan was felt to be particularly appropriate for this trial because, besides being a potent and well-tolerated antihypertensive agent, it has proven to be effective in reversing LVH in the Swedish Irbesartan Left Ventricular Hypertrophy Investigation versus Atenolol (ie, SILVHIA) trial 18 and it also reduced the occurrence of CHF compared with both placebo and amlodipine in Irbesartan Diabetic Nephropathy Trial (ie, IDNT).
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I-PRESERVE was designed to test a RAS inhibitor in a patient population that closely matched the HF-PSF populations described in databases. Because older patients predominate in these databases, I-PRESERVE targeted an older population by excluding patients younger than age 60. The LVEF lower limit criterion was also crucial for a protocol in this area. As noted previously, at the time of design of I-PRESERVE, few clinical trial data existed for heart failure with an ejection fraction higher than 40%. However, available evidencedsuch as in the Duke database 20 (HF-PSF patients selected to undergo cardiac catheterization) with a mean LVEF of 54%dsuggested that the usual LVEF in this syndrome was considerably higher than this level. To best typify the population, and to study patients without systolic heart failure, a minimum ejection fraction of 45% was chosen. The protocol also excluded patients with previous systolic dysfunction, such as those that had an increased ejection fraction during b-blocker therapy or following revascularization, because these patients are likely to be pathophysiologically distinct from other HF-PSF patients.
Unlike systolic dysfunction, with a lower LVEF, HF-PSF does not have an easily ascertained diagnostic marker. Noninvasive measurements of diastolic function have been controversial, but, moreover, are not easily obtained in a large international clinical trial. Although only partially available during the design of I-PRESERVE, the data by Zile and colleagues, discussed previously, confirm that selected patients with HF-PSF invariably have echocardiographic and hemodynamic abnormalities of diastolic dysfunction. 11, 12 These important findings indicate that it is not necessary to routinely measure invasive indices of diastolic function in patients with clinical symptoms and signs of HF-PSF to establish that diastolic heart failure is present. To strengthen the diagnosis of heart failure, I-PRESERVE does require additional clinical criteria for entry which can take 1 of 2 pathways: continuing NYHA II-IV symptoms at enrollment and a heart failure hospitalization within 6 months or continuing NYHA III-IV symptoms, with objective indication of decompensation (chest x-ray), or evidence suggesting a structural basis of diastolic dysfunction (echocardiographic or electrocardiographic evidence). The former pathway, with less advanced symptoms, adds the hospitalization criterion to improve diagnostic accuracy but also to enhance the event rate, because previous data suggest that patients hospitalized for heart failure will likely be hospitalized again within 6 months. 21 The latter pathway requires a higher level of symptoms and also adds structural features suggesting diastolic dysfunction. It is worth noting that the CHARM-PRESERVED protocol did not require either a HF hospitalization or structural criteria for entry. 22 The primary composite endpoint for I-PRESERVE is allcause mortality or protocol-specified cardiovascular hospitalization, analyzed as time to first event. This inclusive endpoint was selected because it optimally reflects the outcomes of this patient population. Although heart failure may be the cause of initial presentation, available data suggest that the minority of cardiovascular events that occur in this population are primarily attributable to heart failure. At the time of trial design, the available clinical trial data, the Digitalis Investigation Group study reported that 60% of hospitalizations had a primary cardiovascular cause, whereas only 20% were primarily from heart failure. 23 More recently the CHARM Preserved investigators have reported similar data. 10 The I-PRESERVE protocol stipulates specific cardiovascular categories of hospitalization that represented potentially realistic targets for therapy: heart failure, unstable angina, myocardial infarction, atrial arrhythmias, and ventricular arrhythmias. Documented myocardial infarction and stroke occurring at any time during the trial are also included as primary end points as they represent irreversible events. The protocol also stipulates that a primary end point hospitalization would require an overnight duration and either parenteral or augmented oral therapy for the prespecified cardiovascular condition.
Because there is no proven therapy for HF-PSF, there is also no obvious mandated therapy. However, patients with HF-PSF are likely to have other comorbidities and require treatment for conditions such as hypertension, coronary artery disease, and atrial fibrillation. Accordingly, because background treatment for these conditions would need to be allowed, only ARB treatment would be an absolute exclusion. However, because there is significant pharmacologic overlap with ARBs, ACE inhibitor therapy was restricted to patients who had a specific indication for these agents, such as diabetic nephropathy or advanced atherosclerotic disease including confirmed myocardial or cerebrovascular infarctions. Entry of patients requiring ongoing use of an ACE inhibitor was limited to one third of the population, because I-PRESERVE was not intended to be a trial of combination ARB and ACE-inhibitor therapy. This level of ACE inhibitor usage was also consistent with that observed in community practice at the time I-PRESERVE was designed.
An important feature of I-PRESERVE concerns natriuretic peptides. Brain natriuretic peptides (BNP) have been noted to be elevated in diastolic heart failure, but observations are limited. Largely for this reason, BNP measurement in any form is not an entry criteria in this study: however, pro-BNP will be measured in all patients at baseline and at 2 points of follow-up. This will be the largest dataset of natriuretic peptides in HF-PSF, and I-PRESERVE will provide strong evidence for the range of values for pro-BNP occurring in this syndrome. Because recent data with BNP in systolic heart failure supports a strong prognostic role, 24 the relation pro-BNP to clinical events in I-PRESERVE will of great interest. Finally, the trial design will assess the effect of irbesartan treatment on pro-BNP levels.
Conclusion
HF-PSF represents a large part of the overall morbidity and mortality burden of chronic heart failure. It is the predominant form of heart failure in the elderly and in women. The I-PRESERVE protocol, the largest HF-PSF study to date, is designed to examine the prognosis and response to irbesartan in an understudied and poorly understood area. 
